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The anaplastic large cell lymphoma (ALCL), a subtype of peripheral T-cell 
lymphoma (PTCL), is a lymphoid malignancy characterized by a “hallmark cells” 
and elevated expression of CD30. Anaplastic lymphoma kinase–positive (ALK+) 
carry ALK fusions, more often the NPM-ALK t(2;5) translocation, while about 
40% of all ALCLs are negative (ALK-). ALK chimeras promote cell survival and 
tumorigenesis by constitutively activating multiple cell signaling pathways, 
including the STAT3 pathway. STAT3 is a member of family Signal Transducers 
and Activators of Transcription (STATs), and its chronic activation has been 
proven to play a role in the pathogenesis of several PTCL malignancies. 
Remarkably, approximately 50% of all ALK- ALCL have been proven to display 
the deregulated activation of the JAK-STAT3 pathway which is required for the 
maintenance of their neoplastic phenotype.  
Here we described a series of pharmacological approaches designed to modulate 
the activity of STAT3 signaling. To achieve this objective, we have focused on 
ALK+ and ALK- ALCL cell lines and PDX models. We have taken advantage of 
two different but complementary molecules: a selective STAT3 binding 
compound named JPX-XX1, and two specific STAT3 degraders (A1 and N1). Both 
JPX-XX1 and A1 and N1 compounds were proven to reduce the cell growth and 
metabolic activity of ALK+ as well as selected ALK- ALCL cell lines, in a dose-
dependent manner. As predicted both degraders were efficiently and selectively 
capable to degrade STAT3, a phenotype that was maintained over time (6 days 
of treatment) after a single dose exposure. Mechanistically, the loss of STAT3 
was associated with a cell cycle arrest and increased apoptosis.  
Collectively our data by confirming previous findings further demonstrate the 
pivotal role of STAT3 signaling in ALCL. More importantly, these compounds 
open new and feasible therapeutic avenues for the treatment of ALCL. A strategy 
that may be successfully applied to other JAK/STAT3 dependent 
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ACRONYMS AND ABBREVIATIONS 
 
7-AAD: 7-Amino-Actinomycin  
Ab: Antibody  
ALCL: Anaplastic Large Cell Lymphoma 
ALK- ALK-negative 
ALK: Anaplastic Lymphoma Kinase  
ALK+: ALK-positive 
ALO17: ALK Lymphoma Oligomerization Partner on Chromosome 17 
AML: Acute Myeloid Leukemia 
ATIC: 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP 
Cyclohydrolase 
BIA-ALCL: Breast Implant Associated Lymphoma 
CCD: Coiled-Coil Domain 
CDX: Cancer-Derived Xenograft 
CLTC-ALK: Clathrin Heavy Chain 
CO2: Carbon dioxide 
CRBN: Cereblon 
DBD: DNA-Binding Domain 
DMSO: Dimethyl Sulfoxide 
E3: E3 ubiquitin ligase 
EGFR: Epidermal Growth Factor Receptor 
EML4: Echinoderm Microtubule-Associated Protein-Like 4 
FBS: Fetal Bovine Serum 
FFS: Failure Free Survival  
HTS: High Throughput Sampler 




IGF-1RK: Insulin-Like Growth Factor Receptor 
INSR: Insulin Receptor  
IRK: Insulin Receptor Kinase 
IRR: Insulin Receptor-Related Receptor  
IRS1: Insulin Receptor Substrate-1  
JAKs: Janus Kinases 
JM: Juxtamembrane  
KD: Kinase Domain  
LTK: Leucocyte Tyrosine Kinase  
MDK: Midkine 
MetAp-2: Methionine Aminopeptidase-2 
MOI: Multiplicity of Infection 
MSN: Moesin 
MYH9: Non-Muscle Myosin Heavy Chain  
NHL: Non-Hodgkin Lymphoma  
NMP: Nucleophosmin 
NTD: Amino-Terminal Domain 
OS: Overall Survival 
PBS: Phosphate-Buffered Saline 
PDGFR: Platelet-Derived Growth Factor Receptor 
PDTX: Patient-Derived-Tumor-Xenograft 
PI: Propidium Iodide 
PI3K: Phosphatidylinositol 3 Kinase 
PIAS: Protein Inhibitor of Activated STAT 
POI: Protein of Interest 
PROTACs: Proteolysis-Targeting Chimeras 
PTCL: Peripheral T-Cell Lymphoma  
PTN: Pleiotrophin  
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RTK: Receptor Tyrosine Kinase  
S1PR: Sphingosine-1-Phosphate Receptor 
SDS-PAGE: Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SEM: Standard Error of the Mean 
SH2: Src Homology-2  
SHC: Src Homology 2 Domain Containing  
SHC1: Shc Transforming Protein 1  
SiRNA: small interfering Rna 
SOCS: Suppressor of Cytokine Signaling 
STATs: Family Signal Transducers and Activators of Transcription 
TAD: Transactivation Domain 
TFG: TRK-Fused Gene 
TLRs: Toll Like Receptors 
TPM3: Ttropomyosin 3  
TPM4: Tropomyosin 4 
UPS: Ubiquitin-Proteasome System 






Clinical and histological features of primary systemic 
ALCL. 
 
Peripheral T-cell lymphoma (PTCL) is a lymphoma of post-thymic origin that 
represents approximately 12–15% of all non-Hodgkin lymphoma (NHL) in 
Western populations [1, 2]. In 1985 Stein and colleges first described anaplastic 
large cell lymphoma (ALCL), a subtype of PTCL, as a lymphoid malignancy 
characterized by marked cellular pleomorphism, propensity to grow cohesively, 
tendency to invade lymph node sinuses and diffuse expression of the Ki-1 
antigen, later designated as CD30 [3]. In 1988, Fischer et al. first described 
chromosomal translocation affecting chromosomes 2 and 5 in a new Ki-1 
positive lymphoma cell line called Karpas 299 [4]. In the next two years, several 
groups confirmed the association of this translocation to most of the Ki-1 
positive lymphomas [5-7]. Just some years later, the product of 
t(2;5)(p23;q35) translocation was identified as the receptor tyrosine kinase 
(RTK) anaplastic lymphoma kinase (ALK) fused to nucleophosmin (NPM1, also 
known as NPM and B23) [8].  
Nevertheless, ~40% of ALCL do not express ALK or other recurrent 
translocations. Although the current World Health Organization classification of 
lymphomas considers among the ALCL the following categories: ALK-positive 
(ALK+) and ALK-negative (ALK-) ALCL, meanwhile the breast associate ALCL 
remains a provisional entity.  Cutaneous ALCL is included within the CD30 
positive T-cell lymphoproliferative disorders [9]. The epidemiology of nodal 
ALCL is unique: ALK+ mostly occurs in pediatric patients, while ALK- occurs in 
older patients with a lower male predominance when compared to the previous 
one. Bone marrow, bone, subcutaneous tissue, and splenic involvement is seen 
at higher frequency in ALK+ patients, whereas skin, liver, and gastrointestinal 
involvement is more frequent in ALK- ALCL [10, 11]. 
Moreover, when treated with aggressive chemotherapy, patients affected by 
ALK+ ALCL have longer failure-free survival (FFS) and overall survival (OS) than 
ALK- ALCL patients (5-year OS: 70–80% vs. 33–49%) [10, 11]. 
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ALCL typically shows a wide spectrum of morphologic features, ranging from 
small-cell neoplasms to cases where very large and anaplastic cells 
predominate. Almost all the cases, however, share a common feature, which is 
the presence of a variable number of so-called “hallmark cells” (Figure 1) [12, 
13]. Specifically, these are large cells with abundant cytoplasm and “horseshoe” 
or “kidney-shaped” nuclei. Hallmark cells are usually large, but in the small-cell 
variants these elements are considerably smaller and more monotonous with 
pale cytoplasm, with a distinct cytoplasmic membrane and irregular nuclei 
mixed with some medium-size and large lymphoid cells. 
Over with these highly characteristic and almost diagnostic hallmark cells, 
neoplastic elements with different morphology are usually seen. Common 
features of ALCL are an invasion of lymphatic sinuses and a perivascular pattern 
of neoplastic cell infiltration. An inflammatory background can be present, 
composed of abundant histiocytes with round–oval nuclei and eosinophilic 
cytoplasm, polymorphonuclear nuclear cells mixed with plasma cells, and rare 
leukocytes. In some cases (25%) significant fibrosis with collagenous bands 







FIGURE 1- Typical hallmark cells of anaplastic large cell lymphoma [12]. H&E staining on 
the left, ALK staining on the right. 
 
The CD30 antigen, a cytokine receptor of the tumor necrosis factor receptor 
superfamily, is strongly expressed by all. The staining pattern is typically 
membranous with strong reinforcement within the Golgi area. However, CD30 
expression is not specific for ALCL and can be seen in activated non-neoplastic 
lymphoid cells, in a subset of B and T cell lymphoma, in Hodgkin’s lymphoma 
and embryonal carcinoma.  
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ALCLs, present an abnormal phenotype with a variable positivity for several of 
T cell and non-T cell markers [14]. Despite the loss of the pan-T cell marker, all 
null ALCL by immunohistochemistry can usually be proven to be lymphoma of 
T-cell origin with clonal T-cell receptor-and -rearrangements. Among the pan-
T-cell markers, only CD2 is most frequently positive, whereas CD3, CD5, CD7, 
andCD45RO are less detectable, with two or more of these negative or weakly 
positive. The CD4 and CD8 are variable and, in most cases, the tumor cells have 
a CD4+/CD8+pheno-type, but CD8+ cases have been described as well [10-12, 
15]. Cytotoxic molecules such as granzyme B, perforin, and T-cell-restricted 
intracellular antigen-1 are almost always expressed. 
The discovery of ALK translocations in ALCL has provided an objective tool for 
the recognition of some of these lymphomas. Because ALK expression, in the 
absence of translocations, has been documented in rare normal elements and 
some nonlymphoid neoplasms, positive ALK stains are highly informative. 
Indeed, the levels of expression of the ALK chimera in ALCL are quite high and 
fusion proteins can be easily detected using specific antibodies against ALK. ALK 
fusion protein expression is reproducibly demonstrated by 
immunohistochemistry in ~ 50% of systemic ALCL, whereas primary c-ALCL is 
always negative.  
ALK, also known as CD246, belongs to the superfamily of insulin receptor kinase 
(IRK), which also includes the insulin-like growth factor receptor (IGF-1RK), the 
insulin receptor-related receptor (IRR), the insulin receptor (INSR), ROS and, 
at last, the leucocyte tyrosine kinase (LTK), which as a high structural homology 
with ALK, and constitutes a distinct subgroup within the IRKs [16, 17]. IRKs are 
an RTK with an extracellular ligand-binding domain, a transmembrane domain 
and a cytoplasmic kinase catalytic region. The extracellular region of ALK 
includes some motifs, including a 26-amino acid N-terminal signal peptide 
sequence, as well as the binding site (at residues 391-401) for the endogenous 
ligands pleiotrophin (PTN) and midkine (MDK) [18, 19].  The 28-amino acid 
transmembrane domain is followed by a 64-amino acid juxtamembrane (JM) 
domain, which contains a binding site of insulin receptor substrate-1 (IRS1), 
facilitating a tyrosine phosphorylation-dependent interaction. The Kinase 
Domain (KD) in the intracellular part includes a three-tyrosine-containing motif 
(Y1278, Y1282, Y1283) within its activation loop, representing the major self-
phosphorylation site of the insulin receptor superfamily. The 244-amino acid 
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ALK C-terminus contains a phosphotyrosine-dependent binding site for the 
substrate protein SHC (Src homology 2 domain- containing) transforming 
protein 1 (SHC1), as well as an interaction site for phosphotyrosine-dependent 
binding of phospholipase  C-c [20, 21]. 
ALK gene is composed of 26 exons; the 6226 bp cDNA encodes for a 177-kDa 
polypeptide that, after post-translational modifications, such as N-glycosylation, 
becomes a mature ALK RTK of approximately 200–220 kDa. 
ALK receptor expression, originally documented in a variety of cancer lines, has 
been documented in many neuronal tumors [19, 22, 23], glioblastoma [24, 25] 
and mesenchymal neoplasms including melanoma [26] and rhabdomyosarcoma 
[8, 27, 28]. 
In this context, ALK overexpression or gain of function mutations have been 
demonstrated to be tumorigenic. ALK expression in hematological disorders 
ALCL, first described in 1985 [3]. 
 
NPM-ALK in ALCL 
 
Many ALK-positive (ALK+) ALCL, around the 90%, express the NPM–ALK fusion 
protein, derived from the t(2;5)(p23;q25) translocation [13]. NPM is a 
multifunctional protein: acts as a molecular chaperone in the transport of pre-
ribosomal particles from the nucleus to the cytoplasm. Moreover, it plays a 
critical role in DNA repair, transcription, and genomic stability as well [29]. The 
N-terminus domain of NPM, within the ALK chimera, provides a dimerization 
domain, essential for chimera autophosphorylation, allowing the constitutive 
activation of the kinase and the firing of downstream signaling [9, 30, 31]. 
The oncogenic potential role of ALK chimeras was first demonstrated in vivo by 
Kuefer and colleagues, subjecting mice to bone marrow transplantation with 
cells transduced with NPM–ALK constructs [32]. One year later, similar results 
were obtained in vitro testing the transforming potential of fibroblasts containing 
NPM–ALK [33]. However, it was in 2003 that the lymphomagenic role of NPM–
ALK was confirmed by generation of a mouse model in which the expression of 
NPM-ALK showed the spontaneous development of T-cell lymphomas and/or 
plasmacytoma [34]; confirmed than by Turner and Alexander by using 
additional mouse models [35]. Several studies have identified that NPM–ALK 
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promotes cell survival and tumorigenesis by constitutively activating many cell 
signaling pathways (Figure 2), including the STAT pathway [9]. 
ALK-dependent mitogenic signaling is largely mediated via Ras/MAP kinase 
pathway through the direct binding of IRS1, SHC, and SRC on specific tyrosine 
residues within the intracytoplasmic segment of ALK. The SHP2/GRB2 complex 
interacts with p130Cas, modifying the cytoskeleton organization as well. In the 
case of ALK-driven phosphatidylinositol 3 kinase (PI3K) activation, a relevant 
anti-apoptotic signal is generated mainly through pAKT1/2, and its downstream 
molecules (inhibition of BAD and FOXO3a-mediated transcription). At the same 
time, the PI3K pathway controls cell cycle progression. An additional oncogenic 
signal may be provided by PLC-g, which binds directly to activated ALK, and 
generating diacylglycerol and IP3 activates PKC and mobilizes calcium stores 
from the endoplasmic reticulum [9]. 
A critical oncogenic player is represented by the JAK/STAT3 pathway, which 
provides essential survival signals and modulates the cellular metabolism 
regulating the mitochondrial oxidation chain. The downstream effectors of 
STAT3 include several members of the BCL2 family (BCL2, BCL-XL, and MCL-1) 








Once STATs are phosphorylated, they dimerize and accumulate in the cell 
nucleus and bind to enhancer elements of target genes. Zamo and colleagues 
[37] have first shown that STAT3 is the key effector molecule of the ALK-
mediated signaling in ALCL and its activation is required for the maintenance of 
the neoplastic phenotype [38]. NPM–ALK can directly phosphorylate STAT3 or 
can activate JAK3, which in turn can contribute to STAT3 activation [9].  STAT3 
phosphorylation in tyr705 results in an increased expression of BCL2, BCL-XL, 
survivin, and MCL-1 proteins, involved in anti-apoptotic processes. STAT3-
mediated signal also leads to uncontrolled proliferation, acting on cell cycle 
regulators such as cyclin D3 and c-myc, often overexpressed in ALK+ lymphoma 
[34, 39]. 
Cooperation between NPM–ALK and JAK/STAT pathway might also lead in a 
certain context to the STAT5 activation, although in T-cell, STAT3 acts as a 
STAT5 repressor [40, 41]. 
 
ALK fusion proteins 
 
In addition to NPM–ALK, many other fusion proteins can be expressed in ALCL, 
namely ALK lymphoma oligomerization partner on chromosome 17 (ALO17), 
TRK-fused gene (TFG), moesin (MSN), tropomyosin 3 and 4 (TPM3 and TPM4), 
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP 
cyclohydrolase (ATIC), non-muscle myosin heavy chain (MYH9), and clathrin 
heavy chain (CLTC–ALK) [36]. Moreover, ALK rearrangements have also been 
detected in large B-cell lymphoma and various tumors of mesenchymal and 
epithelial origin, including inflammatory myofibroblastic tumors, lung cancer, 
esophageal squamous cell carcinoma and others [42]. Notably, the same ALK 
fusions, such as TPM3-ALK, TPM4-ALK, TFG-ALK, SEC31A-ALK, ATIC-ALK, 
CLTC-ALK and EML4 (echinoderm microtubule-associated protein-like 4) -ALK 
occur in ALK+ malignancies of different cells of origin, highlighting the crucial 
role of ALK in tumorigenesis [42, 43]. Collectively, these discoveries have 
encouraged the development of therapeutic strategies regarding ALK+ tumors.  
In 2003, Hubinger and colleagues performed the ablation of ALK protein 
expression, obtained by ALK-specific small interfering RNA (siRNA) duplexes or 
selective ribozyme [44]. This study showed that the ALK knockdown leads first 
to a cell cycle arrest, followed by massive apoptosis in vitro and in vivo some 
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years later [45]. Results that were confirmed applying ALK-specific small 
molecules [46, 47] and subsequently were supported by other novel ATP-
competitive inhibitors [48, 49].  Really important was the discovery of specific 
ALK tyrosine inhibitors, one of which, crizotinib, has proven to have clinical 
efficacy in the treatment of ALK+ non-small cell lung cancer and ALCL [50, 51]. 
Crizotinib (PF-02341066) is a dual MET/ALK inhibitor, that binds into the 
nucleotide pocket of the target kinase and prevents ATP from binding to the 
enzyme [52]. Originally, crizotinib was developed as a selective c-MET inhibitor 
and indeed it showed excellent anti-tumor activity in MET-dependent cancer 
models [52, 53]. While selectivity profiling of the compound was performed, 
ALK resulted as another substrate sensible to the drug. Hence, the drug was 
then studied as an ALK inhibitor [54].  
Afterward, other small molecules have reached the clinics, as LDK378, or the 
pre-clinical stages as CEP28122, CEP37440, AP-26113, and more [55]. 
Since ALK signaling activates multiple downstream molecules, it could be also 
useful to use molecules that can target effectors involved in this pathway to 
treat ALK+ cancer patients. Considering the oncogenetic addition of ALK+ ALCL 
to STAT3, inhibition of this transcription factor could provide a therapeutic target 
[45]. 
 
Signal Transducers and Activators of Transcription 3 
(STAT3) 
 
STAT3 is an important member of family Signal Transducers and Activators of 
Transcription (STATs), that regulates gene transcription that transmits signals 
from activated plasma membrane receptors to the nucleus in response to 
various stimuli [56, 57].  
STATs were first discovered in 1994 and found to be involved in interferon (IFN)-
triggered transcription regulation [58]. Seven different STAT proteins, namely 
STAT1, -2, -3, -4, -5a, -5b, and -6, have been discovered in mammalian cells 
[59].  These proteins can transduce intracellular and extracellular signals that 
mediate multiple cellular functions related to survival, growth, proliferation, and 
angiogenesis [60, 61]. Commonly localized in the cytoplasmic compartment of 
the cell, STATs are present in an inactive state, either as monomers or as 
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unphosphorylated dimers that can be activated by various stimuli such as 
cytokines and growth factors [62, 63].  
Upstreaming STATs are activated by phosphorylation on tyrosine by Janus 
kinases (JAKs), Src family members, as well as growth factor receptors such as 
epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor (PDGFR) [59, 64]. The crystal structure of STAT3-ß bound to a DNA 
molecule (Figure 3) was determined in 1998, offering insight into STAT3 function 





FIGURE 3 – Crystal structure of STAT3β [66]. Color keys: cyan = amino-terminal domain; 
green = coiled-coil domain; red = DNA-binding domain; yellow = linker domain; blue = SH2 




STAT3 consists of 770 amino acids that constitute six different functional 
domains, including amino-terminal domain (NTD), coiled-coil domain (CCD), 
DNA-binding domain (DBD), linker domain, SH2 domain, and the carboxyl-





FIGURE 4 –The molecular structure of the two STAT3 isoforms [67]. 
 
 
The NTD is essential for the cooperative binding of STATs to multiple consensus 
DNA sites. The CCD is critical for the recruitment of STAT3 to the receptor and 
subsequent phosphorylation, dimerization; also, residues essential for nuclear 
translocation are contained. The DBD can recognize a specific molecular motif 
in the DNA. The SH2 domain is important for recruitment and activation and 
dimerization of the STAT3 molecule by interacting with phosphorylated tyrosine 
residues (Tyr705).  The TAD differs between α and β isoforms (Figure 4), with 
the β form having a unique truncated C-terminal sequence. In this domain is 
locate Tyr705 becomes phosphorylated upon activation of STAT3. An additional 
phosphorylation site within the TAD, Serine 727 (Ser727) is important for 
regulating STAT3 activation by serine/threonine kinases such as the MAPKs 
(mitogen-activated protein kinases) [67, 68]. 
STAT3 is activated by binding of a ligand to its receptor on the cell surface. 
Ligand binding leads to activation of JAK, which recruits and phosphorylates 
STAT3. STAT3 then forms a dimer, moves into the nucleus and controls 
transcription. Upstream signals that can trigger JAK kinase-mediated 
phosphorylation on Y705 (YP) range from cytokines of the IL-6 family, leptin, 
IL-12, IL-17, IL-10, interferons, growth factors such as G-CSF, EGF, PDGF, and 
some oncogenes, the prototype of which is Src family kinases but also including 
Abl, Sis, Fps, Ros, Met and ErbB2 [69-71]. Moreover, G protein-coupled 
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receptors, like the sphingosine-1-phosphate receptor (S1PR) 1, and several toll-
like receptors (TLRs) have been shown to activate STAT3[69, 72]. 
 
 
FIGURE 5 – Schematic representation of STAT3 signaling cascade [67]. 
  
In physiological conditions, STAT3 activation is controlled by three groups of 
negative regulators: phosphatases, suppressor of cytokine signaling (SOCS) 
proteins, and protein inhibitor of activated STAT (PIAS) proteins [73, 74]. 
Phosphatases like SHP-1, SHP-2, PTP1B or T cell PTP terminate STAT3 
activation, acting either at the level of JAK kinases or directly in the nucleus 
[73]. SOCS3, of SOCS family, is a primary transcriptional target of STAT3 and 
acts as a negative feedback regulator to inhibit JAK activity, while PIAS3 
prevents the binding of STAT3 to its target DNA sequence [75, 76]. Chronic 
STAT3 activation in tumors is known to occur downstream of aberrant upstream 
stimulation [77]. Furthermore, STAT3 somatic mutations have been shown to 
play a role in the pathogenesis of hematopoietic malignancies [78, 79]. 
Recently, recurrent mutation is discovered in ALK- ALCL panel, suggesting that 
a STAT3-mediated oncogenic mechanism may be shared by all ALCLs, 
independent of ALK status. Mutation recurrence of JAK/STAT3 genes in ALK- 
ALCL was largely studied by Inghirami’s team that sequenced 155 primary ALCL 
samples (between ALK- and ALK+) and 74 PTCLs (included angioimmunoblastic 
18 
 




Innovative therapeutic approaches for STAT3 target 
 
Despite the role of STAT3 as a potential therapeutic target, the development of 
STAT3 inhibitors for clinical use has been slow. 
Inhibition of the up-stream pathway as JAK kinase can decrease the 
phosphorylation and activity of STAT3. However, the use of this kind of 
inhibitors, such as ruxolitinib, has a relatively weak effect on STAT3 and 
demonstrates only a modest clinical benefit in patients with STAT3-driven 
malignancies [81].  
Different studies focused the attention on developing inhibitors of STAT3 DNA 
binding domain and STAT3 SH2 domain that would prevent dimerization and 
transcriptional activity of STAT3 [82-84]. Although many of these inhibitors 
have reached the clinical development stage, they demonstrated very limited 
clinical activity [85]. One issue with STAT3 SH2 inhibitors is the limited 
selectivity, as STAT family members share a highly structurally homologous SH2 
domain. The second issue is that these small molecule inhibitors block STAT3 
dimerization and only partially suppress the gene transcriptional activity of 
STAT3 since monomeric STAT3 protein also has transcriptional activity [86]. 
Lastly, monomeric STAT regulates critical mitochondrial activities, control cell 
shape, and motility. Properties that are not inhibited by conventional inhibitors. 
However, in 2001 a new and attractive approach started into small-molecule 
development. Crews and Deshaies laboratories reported a study based on the 
induction of ubiquitylation and degradation using a proteolysis-targeting 








FIGURE 6– Schematic representation of bifunctional small molecules that prompt an 
unwanted protein to be tagged with ubiquitin, sending it to the cellular trash bin. 
 
A PROTAC is a heterobifunctional molecule that consists of a protein of interest 
(POI) ligand and an E3 ubiquitin ligase (E3) recruiting ligand connected by a 
linker. PROTACs initiate a degradation cascade by forming a ternary complex 
with a POI and an E3, bringing the ubiquitination machinery nearby for 
subsequent POI ubiquitination. The polyubiquitinated POI is then recognized and 
degraded by the 26S proteasome. The 26S proteasome is part of the ubiquitin-
proteasome system (UPS) which is the primary mechanism used by eukaryotic 
cells to regulate protein levels [88, 89]. In the last years, PROTAC strategy has 
begun to be more popular, and different proteins, nuclear receptors, and kinases 
were targets to develop new molecules [90]. Recently, Bai and colleagues 
showed the results of PROTAC degrader of STAT3 named SD-36. SD-36 was 
designed using an analog of cereblon (CRBN) ligand, lenalidomide, and the 
STAT3 SH2 domain inhibitor SI-109 previously developed [91]. 
This bifunctional molecule binds to the STAT3 SH2 domain via one functional 
group and CRBN via the other functional group. Once near STAT3, CRBN then 
forms an E3 ubiquitin ligase complex that recruits an E2 enzyme to ubiquitinate 






Figure 7- STAT3 Degraders Inhibit Oncogenic STAT3 Signaling by Targeting STAT3 
Proteins for Proteasomal Degradation [92].  The figure shows the different mechanisms of 
action of inhibitors compares to degraders.  STAT3 inhibitors typically reduce STAT3 activity by 
blocking STAT3 tyrosine phosphorylation, STAT3 dimerization, or STAT3 DNA binding. In contrast, 
STAT3 degraders block STAT3 activity by triggering the degradation of the STAT3 protein. 
 
 
Bai and colleagues showing that SD-36 inhibits STAT3 dimerization, STAT3 DNA 
binding, STAT3-dependent reporter gene activity, STAT3 target gene 
expression, and STAT3-dependent proliferation in acute myeloid leukemia (AML) 
and ALCL cell lines. They also evaluated the therapeutic potential of SD-36 in 
three different mouse xenograft tumor models [91]. 






Patient-Derived-Tumor-Xenograft (PDTX) model 
 
Cancer cell lines still represent the most common models in cancer research and 
anticancer drug discovery in vitro. They have many advantages including the 
immediate accessibility to the scientific community and the reproducibility of 
results. The heterogeneity of the tumor environment led to developing a model 
that can accurately reproduce and predict in vivo drug sensitivity and response 
to patients, thus supporting in vitro research and cancer cell line results. 
Patient-Derived-Tumor-Xenograft (PDTX) model, which was first described 
more than 40 years ago, may represent a valuable help for cancer research and 
drug discovery, not just for in vivo but also for in vitro research [93, 94]. 
PDTX model consists of the transplantation of a fresh human tumor specimen 
from a cancer patient directly into the immune-deficient mice. The 
histopathology of PDTX tumors closely mimics those of the donor lesions. A lot 
of evidence, including high fidelity in mutational status, transcriptome, 
histology, polymorphism, and copy number variation, also supports the notion 
that PDTX models remarkably resemble the pathophysiology of human tumors 
more closely than traditional cancer-derived xenograft (CDX) models [95]. 
 
 
FIGURE 8– Schematic representation of PDTX generation: engraftment and expansion 




In the case of solid neoplasms, after sample collection, tumors are rapidly 
processed and tissue fragments (≈3mm3) are implanted via multiple routes, 
more frequently subcutaneously or orthotopically. The implantation of tissue 
fragments provides a rational advantage in maintaining the overall organization 
of the neoplastic microenvironment and ultimately preserves neoplastic niches. 
In the setting of liquid tumors, cancer cells are instead purified (gradient 
separation, etc.) and implanted (intravenous, intraperitoneal, intraspleen-liver, 
intrabone) in immunocompromised host animals [95]. The time of engraftment 
varies considerably between different cancers and among different xenograft 
belonging to the same tumor type. Usually, the growth takes about 2-3 months, 
but longer periods (>6-9 months) are not unusual. Technically, different factors 
can influence the rate of engraftments, such as the quality of the patient-derived 
material, tumor type, stage of differentiation, drug resistance, time of implant, 
number of cells, and routes of implantation. Perhaps the most critical variable 
is the selection of mouse strain. The development of RAG or NOD/SCID/ 
IL2Rγnull (NSG) mice represents a major achievement and has improved 
engraftment of primary human tumor specimens [96]. 
NSG mice are Scid deficient (bearing a DNA repair complex protein Prkdc 
mutation) resulting in profound defects in both B and T cells. They also harbor 
a target mutation of the gene encoding the IL2-receptor common y chain 
(IL2rgnull) and the lack of signaling through IL2rg results in the functional 
impairment of NK cells, thus severely compromising both the innate and 
adaptive immunities in these animals [97]. Moreover, engineered NSG mice 
have emerged for specific applications (i.e. AML) and to generate more reliable 
humanized mice.  
Inghirami’s laboratory has developed a library of multiple PDTX models including 
64 models from primary naïve or relapsed/refractory T-cell lymphoma (showed 





TABLE 1 – Library of multiple PDTX models developed by Inghirami’s laboratory. 
 
For our research, we took advantage of established ALK+ and ALK- ALCL PDTX 
models, which were previously generated, which closely recapitulate their 
original primary lymphoma. We have selected those bearing genomic defects 
leading to the constitutive activation of the STAT3 pathway.  




FIGURE 9 – Generation of PDX derived tumor cells (Created in BioRender.com). The 
generation of PDX derived tumor cells accurse after isolation of the tumor from the host animal. 
Subsequently, after digestion of the tumor, cells are maintained in culture medium supplemented 
or not of interleukins to help the growth. Fibroblasts are left to support the tumor cells growth in 
vitro. When the tumor cells start to grow, they were isolated from fibroblasts and maintained in 




In particular, the experiments were performed on PDX derived tumor cells as 
Belli, ALK- ALCL, carrying mutations in both Jak1/Stat3; IL89, a breast implant-
associated lymphoma (BIA-ALCL), with a Jak1 mutation; IL2 PTCL-NOS carrying 




















MATERIALS AND METHODS 
 
Cell lines  
ALK-positive ALCL human cell lines SUPM2, SU-DHL1, L82 and Karpas 299, and 
ALK-negative BIA-ALCL cell lines TLBR1 and TLBR2 were maintained in RPMI-
1640 medium (Lonza). The medium was supplemented with 10% fetal bovine 
serum (FBS; Corning), 1% penicillin and streptomycin (100 IU/mL of penicillin 
and 100 µg/mL of streptomycin; MP Biomedicals) and 1% glutamine (200mM, 
Thermo Fisher Scientific). The medium for TLBR1 and TLBR2 was supplemented 
with recombinant human interleukin as rhIL-2 (10.000 units/ml). Cells were 
maintained in a 5% CO2 humidified atmosphere at 37°C. 
 
PDX derived tumor cells 
IL2 (PTCL), IL89 (BIA-ALCL), IL142A (ALK- ALCL), Belli (ALK-ALCL) and DNO3 
(ALK+ ALCL) PDX derived tumor cells were maintained in RPMI-1640 medium 
(Lonza). Medium was supplemented with 20% FBS (Corning), 1% penicillin and 
streptomycin (10,000 units/mL of penicillin and 10,000 µg/mL of streptomycin; 
MP Biomedicals), 1% normocin (InvivoGen) and 1% glutamine (200mM, 
Thermo Fisher Scientific). The medium of IL2 and Belli was supplemented with 
recombinant human interleukin as rhIL-2 (10.000 units/ml) and rhIL-15 (10 
µg/mL). Cells were maintained in a 5% CO2 humidified atmosphere at 37°C. 
 
Human peripheral blood mononuclear cells: isolation and 
activation 
Human peripheral blood mononuclear cells (PBMCs) from normal donors were 
isolated by density-gradient centrifugation using Ficoll-Paque PLUS density 
gradient media (GE Healthcare).  PBMCs were maintained in RPMI-1640 medium 
(Lonza), supplemented with 10% FBS (Corning), 1% penicillin and streptomycin 
(100 IU/mL of penicillin and 100 µg/mL of streptomycin; MP Biomedicals),1% 
glutamine (200mM, Thermo Fisher Scientific). PBMCs were activated with 
magnetic beads conjugated to anti-human CD3 and CD28 antibodies 
(Dynabeads Human T- Activator CD3/CD28; Gibco), following the 
manufacturers’ instructions. Cells were maintained in a 5% CO2 humidified 





JPX-XX1 (from Janpix), A1 and N1 (from Kymera Technology) compounds were 
resuspended in dimethyl sulfoxide (DMSO; Sigma) and stored following the 
manufacturer’ s instructions. They were added to the cells at the indicated 
concentration and (different time points). DMSO was used as control. 
 
Metabolic activity 
The presence of metabolically active cells was detected by a luminescent assay. 
Cells were collected in a 96-well black side plate at different time points after 
treatments. The CellTiter-Glo Luminescent Cell Viability reagent (Promega) was 
added to a 1:1 cell-reagent ratio.  The plate was incubated at room temperature 
for 10 minutes to stabilize the luminescent signal.  Luminescent signal was 
detected by a microplate reader Biotek Synergy 4. 
 
Caspase 3/7 activity assay 
Caspase-3 and 7 activities were measured by a luminescent assay. Cells were 
collected in a 96-well black side plate at different time points after treatments. 
The Caspase-Glo 3/7 reagent (Promega) was added to a 1:1 cell-reagent ratio.  
The plate was incubated at room temperature for 1 hour to stabilize the 
luminescent signal.  Luminescent signal was detected by a microplate reader 
Biotek Synergy 4. 
 
Transduction 
Karpas 299 cell line, Belli and IL89 PDX derived tumor cells were transduced 
with a lentiviral bicistronic reporter vector encoding fluorescent ubiquitination-
based cell cycle indicator probes (Fucci) [98]. The Fucci lentiviral vector 
expresses mVenus-hGem (1/110) fused to mCherry-hCdt1(30/120) by the T2A 
peptide using an EF1 promoter that generates optimal levels of gene expression 
in progenitors. These fluorescent reporters can distinguish three cell cycle 
phases as G1 by red fluorescence, G1/S by yellow fluorescence, and S/G2/M by 
green fluorescence. 
Cells were transduced at a concentration of 1 × 106 cells per milliliter at the 
indicated multiplicity of infection (MOI) in the same medium of culture. At 16 
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hours post transduction cells were washed and maintained in the same medium 
of culture. The mVenus and mCherry expression in transduced cells were 
measured 7 days post-transduction by flow cytometry.  
 
Western Blot 
Cells were washed with cold PBS, pelleted and lysed. The protein extracts were 
prepared using the Lysis Buffer [10 mM MgCl2, 150 mM NaCl, 1% NP40, 2% 
glycerol, 1 mM EDTA, 25 mM Hepes (pH 7.5)] plus protease and phosphatase 
inhibitors (PMSF, NaF, Na3VO4, DTT, and PIC). Total protein concentrations 
were measured using the Lowry assay DC Protein Assay Kit (Bio-Rad), according 
to the manufacturer’s protocol. Equal amounts of proteins were subjected to 
SDS-PAGE (6-12% polyacrylamide gels), transferred to PVDF membrane (GE 
Healthcare) by electroblotting, and blotted with rabbit polyclonal antibody (Ab) 
raised against p-STAT3 (Tyr705)  (1:500 dilution, Cell Signaling Technology 
#9131); mouse anti-STAT3 (124H6) monoclonal Ab (mAb) (1:1000 dilution, 
Cell Signaling Technology #9139); ); rabbit anti-STAT5 mAb (1:1000 dilution, 
Cell Signaling Technology #94205); rabbit anti-p27 polyclonal Ab(1:1000 
dilution, Cell Signaling Technology #2552); rabbit anti-Caspase3 mAb (1:1000 
dilution, Cell Signaling Technology #14220); rabbit anti-ALK mAb (1:1000 
dilution, Cell Signaling Technology #3633). A rabbit anti-Actin mAb (1:1000 
dilution, Cell Signaling Technology #8457) and a mouse anti-GAPDH mAb 




All cytometric analyses were performed using the FACSCanto III and Celesta 
instruments (BD Biosciences) and analyzed with the BDFACSDiva software and 
DeNovo FCS Express 7 software.  
 
Cell Viability assay 
Cells were stained with Fixable Viability Stain 700 (FVS700; BD Horizon™), 
according to the manufacturer’s protocol. At different time points after drug 
treatments, cells were harvested, washed and resuspended in PBS containing 
28 
 
FVS700 and incubated for 15 minutes at RT in the dark. After incubation cells 
were washed with PBS and cell viability was analyzed at flow cytometry. 
FVS700 is excited by the red laser (with an excitation maximum of 657 nm) and 
has a fluorescence emission maximum of 700 nm. This dye can be read out of 
filters commonly used for BD Horizon™ APC-R700 or Alexa Fluor® 700. 
 
Annexin V assay 
Cells were stained for annexin V using the Annexin V-PE Apoptosis Detection Kit 
I (BD Biosciences) according to the manufacturer’s protocol. Briefly, following 
drug treatments at different time points, 1X105 cells were pelleted and washed 
twice with ice-cold PBS and resuspended in 100 µl of 1X Annexin V Binding 
Buffer. Subsequently, 3 µl of Annexin V-PE and 3 µl of 7-Amino-Actinomycin (7-
AAD) were added to the cells that were then incubated for 15 minutes at room 
temperature in the dark. After incubation, 100 µL of 1X Annexin V Binding Buffer 
was added to the stained cells and the cells analyzed by flow cytometry.  
 
Cell Cycle assay 
For analyzing the cell cycle distribution cells were stained using the Propidium 
Iodide Flow Cytometry Kit (Abcam) according to the manufacturer’s protocol. 
At different time points after drug treatments, cells were harvested and washed 
with PBS. The cell pellet was resuspended in 400µl cold PBS and cells were 
subsequently fixed with 800 µl 100% cold ethanol, overnight at 4°C. The next 
day fixed cells were pelleted and washed twice with cold PBS and stained in 200 
µL 1X Propidium Iodide (PI) + RNase Staining Solution and incubate at 37ºC in 




Transduced cells were stained with Fixable Viability Stain 575V (FVS575V; BD 
Horizon™), according to the manufacturer’s protocol. At different time points 
after drug treatments, cells were harvested, washed and resuspended in PBS 
containing FVS575V and incubated for 15 minutes at RT in the dark. After 
incubation cells were washed with PBS. Subsequently, cell cycle phases of viable 
cells were analyzed at flow cytometry. 
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FVS575V is excited by the Violet laser (with an excitation maximum of 396 nm) 
and has a fluorescence emission maximum of 572 nm. This dye can be read out 
of filters commonly used for BD Horizon Brilliant Violet 605 (eg, 610/20) or 
Pacific Orange (eg, 575/20). 
 
Drug Screening  
Cells were stained with CellTrace™ Violet Cell Proliferation Kit (Thermo Fisher 
Scientific), according to the manufacturer’s protocol. Cells were incubated at a 
concentration of 1×106 cells per milliliter with Cell Trace (1 µM/mL). After 
incubation cells were washed with PBS, resuspended in the same medium of 
culture at the concentration of 8x104/100 µL and seeded in a 96-well U-bottom 
plate. Subsequently, cells were treated with A1 or N1 compound (500nM) in 
combination with a library of 40 different drugs (1µM) and maintained in a 5% 
CO2 humidified atmosphere at 37°C. After 72 hours cells were washed, 
resuspended in PBS and stained with PI (10 µg/mL) for 10 minutes at 4 °C. 
Subsequently, the drug screening was analyzed at flow cytometry by high 
throughput sampler (HTS; BD). 
 
Statistical analysis  
In all studies, values are expressed as mean ± standard deviation (SD). 
Statistical analyses were performed by unpaired Student’s t-test or ANOVA for 
multiple comparisons, as indicated, with GraphPad Prism 8. 
Differences were considered statistically significant at p<0.05.  
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AIMS OF THE THESIS 
 
The main objective of this study is unveiling new approaches to inhibit the 
biological function of STAT3 in models proven to be addicted to STAT signaling. 
In the past, multiple approaches have been envisioned either to down-regulated 
the JAK-STAT3 signaling (i.e. JAK inhibitors) or to directly down-modulated the 
expression of STATs (RNAi, etc.). Although encouraging data were generated 
using these tools, many of these approaches resulted in only partial inhibition 
or required a long period of exposure at high (toxic) doses; liabilities which have 
impaired the entry of many targeting agents into the clinics. Although 
interesting data were generated suing RNAi, transcriptional inhibition remains 
largely unfeasible in vivo. To overcome these limitations, we selected two 
different sets of compounds derived from two different and complementary 
strategies, selectively targeting STAT to define their properties and their 
potential therapeutic activities in pre-clinical settings. The ultimate goal was to 
identify novel reagents that could be eventually tested in future clinical trials. 
For this purpose, the biological and functional characterization of new small-
molecules with two different STAT3-blocking functional activity has been made. 
We aim to define the biological and chemical properties, the therapeutic efficacy 
of novel anti-STAT compounds using an array of bona fide cells and PDX models 
in vitro. These studies are designed to identify the best reagent to further study 
STAT3 mediated transcriptional regulations and underling the mechanisms 
leading and maintaining the neoplastic phenotype of STAT3 dependent T-cell 
lymphoproliferative disorders. Toward this end, we investigated: 
 
1. Specific STAT inhibitors: these agents were selected from a large library 
of compounds and proven to covalently bind to STAT.  
 
2. Specific degraders of STAT3: these reagents were discovered using an in-
silico approach predicting the binding of STAT3 and known E-ligases. 
Chemical modifications were then implemented to improve binding 






1.Specific STAT inhibitors. 
 
In collaboration with Janpix, a small firm licensed to take into the clinics a novel 
family of small molecule scaffolds derived from the Gunning lab at the University 
of Toronto, we selected two potent molecules selective binding to STAT3/5 or 
STAT3 only.  These inhibitors were previously shown to target the SH2 domain 
at nanomolar concentration, suppress STAT phosphorylation, inhibit 
downstream transcription targets at suitable pharmacokinetic profiles. Janpix 
has further identified small molecules that inhibit STAT3 and STAT5 selectively 
as well as pan-STAT3/5 inhibitors. These agents have shown excellent efficacy 
in preclinical models of medulloblastoma, breast, leukemias as well as other 
STAT dependent cancers. JPX-XX1 and JPX-XX2 compounds were selected by 
the principles of molecular recognition and computational modeling, seeking to 
create small-molecule inhibitors of the dimerization event between two STAT 
proteins. In this project, we have focused on a single molecule, JPX-XX1, which 
displays a selective activity against STAT3. These molecules were provided to 
us and protected by a CDA and MTA between the Janpix and Weill Cornell 
Medicine. 
The JPX-XX1 compound was first tested at different concentrations for 3 days. 
ALK+ cell cells were exposed in parallel to a selective ALK inhibitor (crizotinib) 
as a positive control.  To improve drug efficacy, we then performed a set of 
experiments in which the drug, at the appropriate concentration, was refilled 
every 24 hours. Cells were harvested at 72 hours and evaluated. Representative 
data are presented in Figure 10. As depicted in Panel A, cell viability was reduced 
only in ALK+ ALCL (SUMP2 and SUDHL-1) cells at the highest concentration. No 
changes were seen in ALK- ALCL (IL89 and IL2). When we performed a 
metabolism assay, the data were in line with the previous cell vitality findings 




Figure 10. The JPX-XX1 compound effectively inhibits ALK+ ALCL cells. Cells (5x105/ml) 
were treated with a single dose of Crizotinib (0.2 μM) at day one, while three different 
concentration of JPX-XX1 compound (0.25 μM, 0.5 μM and 1 μM) were used with a refilling every 
24h. All the cells were left in the same media and harvested after 72h and evaluated by viability 
(A), metabolism (B) and count (C). Data represent the mean ± SD of three independent 
experiments. P values are for One-Way ANOVA with Dunnett's multiple comparison versus no 
treated cells (NT). 
 
Lastly, we evaluated the DNA content of the treated cells. Representative 
findings are depicted in Figure 11. As anticipated from the data presented in 
Figure 10, ALK+ ALCL cells were highly sensitive to crizotinib displaying a high 
rate of cell death. Only at 1µM concentration, JPX-XX1 was associated with an 
increased number of dead cells and a decreased fraction of cells in the S-G2 
phase (Figure 11A, B), in both ALK+ ALCL and PTCL cells (Figure 11C). 
Interestingly, IL-89, a BIA-ALCL carrying an activating mutation of the JAK-








































































































































































































































































































































































































































































































Figure 11. JPX-XX1 increases the number of dead cells when DNA content analyses are 
performed. Cells (5x105/ml) were treated with a single dose of Crizotinib (0.2 μM) at day one, 
while three different concentration of JPX-XX1 compound (0.25 μM, 0.5 μM and 1 μM) were used 
with a refilling every 24h. All the cells were left in the same media and harvested after 72h. Data 
represent the mean ± SD of three independent experiments. P values are for 2Way ANOVA with 
Dunnett's multiple comparison versus NT. 
Since responses were obtained at the highest concentration, we next wondered 
whether the effect was specific or alternately linked to general toxicity. Although 
the cell of origin of ALCL remains still controversial (i.e. thymocytes, Th17 cells), 
we thought to use peripheral blood T cells as a surrogate. Moreover, these 
elements could give some idea on the possible toxicity to which cells could be 
exposed in the blood after drug challenge. Towards this end, we isolated 
peripheral blood mononuclear cells from healthy donors and exposed them to 
increasing concentration of the drug. Since resting cells are less susceptible to 
toxicity, we also compared resting versus activated T-cells. Activated cells were 
generated engaging CD3+ cells to coated beads conjugated to anti-human CD3 
and CD28 antibodies for 72 hours. As depicted in Figure 12A, engagement of 
CD3 + second signals was effective. Exposure to the highest concentration was 





























































































































































death as suggested by the Annexin staining (Figure 12D, E). These data were 
supported by the ATPlite readouts of activated cells, meanwhile resting cells did 








Figure 12. At the highest 
concentration JPX-XX1 
increases the number of 
apoptotic cells in both 
resting and activated T-
cells. PBMCs from the donor 
were activated as described 
above (A). Both resting and 
activated T-cells (8X104/0.2 
ml) were treated with a 
single dose of JPX-XX1. All 
the cells were left in the 
same media and harvested 
after 72h and evaluated by 
cell count (B, C), viability 
(D, E) and metabolism (F, 
G). Data represent a single experiment. The duplicate was available just for count and metabolic 
assay. P values are for One-Way ANOVA with Dunnett's multiple comparison versus no treated 
cells (NT). No treated activated cells (NT activated) and no treated resting cells (NT resting) were 






















































































































































































































































































Annexin of activated T cells Annexin of resting T 
cells 
D E 

















































































































2.Specific degraders of STAT3 
 
Degraders exploit the intracellular ubiquitin-proteasome system to selectively 
eliminate target proteins. Two selected STAT3 compounds were provided to us 
by Kymera Therapeutic under a specific CDA and MTA.  Kymera has developed 
a discovery engine that is fueled by unique algorithms and sophisticated 
workflows. Using a holistic approach to drug discovery and development, 
Kymera can fine-tune the potency of drug candidates based not only on their 
drug-like properties but also on their relationship with target properties and 
downstream PK/PD effects. Targeted protein degradation using this technology 
is emerging as a novel therapeutic method to address diseases driven by the 
aberrant expression of a disease-causing protein. Degrader molecules are 
bifunctional small molecules that simultaneously bind a target protein and one 
of the E3-ubiquitin ligases, thus causing ubiquitination and degradation of the 
target protein by the proteasome. Like small molecules, degrader molecules 
possess good tissue distribution and the ability to target intracellular proteins, 
even in the nuclear compartment. To test these tow STAT3 compounds, we have 
selected conventional ALK + ALCL cell lines (L82 and Karpas 299) and ALK- 
ALCL PDTX models (IL89 and Belli). 
A1 and N1 degraders were first tested at different concentrations in a time-
course experiment. Serial dilutions of the drugs were performed to obtain a wide 
concentration curve. Cells were exposed for 3 days to a single administration of 
the compounds, and every 24 hours, cells were harvested and evaluated by 
metabolic assay (Figures 13,14,15 and 16). As depicted in Figures 13 and 15, 
ALK+ ALCL cell lines were highly sensitive to both degraders, even at lower 
concentrations, with a reduction of metabolic activity at 48 hours. No changes 
were seen in IL89, while Belli showed a more significant sensitivity to A1 
degrader after longer exposures (Figure 14C). Remarkably, as for JPX-XX1, IL-
89 was resistant. 
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Figure 13. The A1 degrader starts to reduce the metabolic activity of ALK+ ALCL cells 
after 48h. Cells (1X104/0.1 ml) were seeded in a 96-well plate and treated with a serial dilution 
of A1 degrader, with a single administration. Cells were left in the same media and harvested 
after 24h (A, D), 48h (B, E) and 72h (C, F), and evaluated by metabolic assay. Data represent 
the mean ± SD of four experiments. P values are for One-Way ANOVA with Dunnett's multiple 














Figure 14. The A1 degrader reduces the metabolic activity of Belli. Cells (1X104/0.2 ml) 
were seeded in a 96-well plate and treated with a serial dilution of A1 degrader, with a single 
administration. Cells were left in the same media and harvested after 24h (A, D), 48h (B, E) and 
72h (C, F), and evaluated by metabolic assay. Data represent the mean ± SD of four experiments. 
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Figure 15. The N1 degrader starts to reduce the metabolic activity of ALK+ ALCL cells 
after 48h. Cells (1X104/0.1 ml) were seeded in a 96-well plate and treated with a serial dilution 
of N1 degrader, with a single administration. Cells were left in the same media and harvested 
after 24h (A, D), 48h (B, E) and 72h (C, F), and evaluated by metabolic assay. Data represent 
the mean ± SD of four experiments. P values are for One-Way ANOVA with Dunnett's multiple 














Figure 16. The N1 degrader is not effective to reduce the metabolic activity of ALK- ALCL 
cells. Cells (1X104/0.1 ml) were seeded in a 96-well plate and treated with a serial dilution of N1 
degrader, with a single administration. Cells were left in the same media and harvested after 24h 
(A, D), 48h (B, E) and 72h (C, F), and evaluated by metabolic assay. Data represent the mean 
± SD of four experiments. P values are for One-Way ANOVA with Dunnett's multiple comparison 
versus DMSO. 
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Next, to validate the efficiency of the degraders, we performed a series of 
western blot analyses. In these experiments, we treated the target cells with 
three different concentrations of the degraders, and we used the DMSO as a 
control vehicle. Cells were harvested and lysed (24h), and proteins were used 
for western blot analysis to detect phospho-STAT3, total STAT3, and actin as a 
control (Figure 17). Loss of STAT3 was documented in each cell line, although 
the degree and the kinetics were quite different among all of them. Notably, 
ALK+ ALCL cell lines showed a significant loss which occurs with the lowest 
concentrations (Figure 17A, B), with both degraders. Conversely, ALK- ALCL 
were more resistant and loss of STAT3 was documented at the highest 
concentrations (Figure 17C and D). Interestingly Belli and IL-89 display a 
selective sensitivity to these two degraders, suggesting that specific E-ligases 
may play a different role in these cells. 
 
 
Figure 17. The loss of p-STAT3 and total STAT3 after 24 hours of treatment with A1 and 
N1 degraders. Cells (2X105/ml) were treated with three different concentrations of A1 and N1 
degraders. DMSO was used as control. After 24h of the single administration of the drugs, cells 
were harvested and lysed. Proteins were separated by electrophoresis, transferred to the PVDF 
membrane, and incubated with antibodies against p-STAT3, total STAT3, and actin as a control.  
Next, we performed a set of experiments designed to dissect further the kinetics 
and drug efficiency over time.  Towards this end, we first exposed the cells to 
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different concentrations of A1 or N1 for a longer time (> 72h). At day three the 
cells were randomized two different arms: half cells were left in the same 
condition without a drug refilling; meanwhile the remaining cells were cultured 
with new media and new drugs.  In both cases, cells were harvested every 24h 
and evaluated by caspase 3/7 activity assay (Figure 18). To perform these 
experiments, we matched the best degrader for each cell line (Figure 17). 
As depicted in Figure 18, at the highest concentration we observed an increased 
cell death rate as documented by the Caspase assay. Remarkably, when the 
cells were refed, cell viability was apparently restored. Data which could be 
linked to the decreased number of viable cells at 96hr pre-refilling (Figure 18). 
To supports these data also we performed time-course assays as well as cell 
count (Figure 19) and Annexin V (Figure 20). Overall these data demonstrated 
that there was an increased cell death overtime and dose-response in both ALK+ 
ALCL and Belli. Remarkably IL-89 was refractory. 
 
 
Figure 18. Caspase 3 and 7 activities increased for L82 and Belli after treatment with 
A1. Cells (2X105/ml) were treated with four different concentrations of degraders, with a single 
administration at day 0. L82 (A), Karpas 299 (B) and Belli (C) cells were treated with the degrader 
A1, while N1 was used to treat IL89 (D). After 72h of treatment cells were split in two: half cells 
were left in the same media without refilling of the drugs; the other half cells were washed with 
PBS, counted, restored at the same condition as day 0 (2X105 cells per ml, refilled of new media 
and new drugs). All the cells, refilled or not at day 3, were collected every 24h and evaluated by 
caspase 3/7 activity assay. Data represent the mean ± SD of three experiments. P values are for 
2Way ANOVA with Dunnett's multiple comparison versus DMSO. 
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Figure 19. A1 degrader reduces the number of L82, Karpas 299 and Belli with or without 
refilling. Cells (2X105/ml) were treated with four different concentrations of degraders, with a 
single administration at day 0. L82 (A), Karpas 299 (B) and Belli (C) cells were treated with the 
degrader A1, while N1 was used to treat IL89 (D). DMSO was used as control. After 72h of 
treatment cells were split in two: half cells were left in the same media without refilling of the 
drugs; the other half cells were washed with PBS, counted, restored at the same condition as day 
0 (2X105 cells per ml, refilled of new media and new drugs). All the cells, refilled or not at day 3, 









































L82 treated with A1 A 
































KARPAS 299 treated with A1 B 































BELLI treated with A1 C 




































Figure 20. A1 degrader increases the number of apoptotic cells of L82, Karpas 299 and 
Belli in a time course experiment. Cells (2X105/ml) were treated with four different 
concentrations of degraders, with a single administration at day 0. L82 (A), Karpas 299 (B) and 
Belli (C) cells were treated with the degrader A1, while N1 was used to treat IL89 (D). DMSO was 
used as control. After 72h of treatment cells were split in two: half cells were left in the same 
media without refilling of the drugs; the other half cells were washed with PBS, counted, restored 
at the same condition as day 0 (2X105 cells per ml, refilled of new media and new drugs). All the 
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To interpret these data and gain some insights into the mechanism of action, 
we performed a new set of western blot analyses. Cells were exposed to drugs 
and harvested at 96h or 144h. Cells were lysed, and proteins were used for 
western blot analysis to detect total STAT3 and actin or GAPDH as a control 
(Figure 21). In these experimental conditions, the protein expression of total 
STAT3 significantly reduced even at the lowest concentrations and virtually no 
signals were detectable at longer exposures in samples treated with >1µM. 




Figure 21. The loss of total STAT3 after long exposure of treatment with A1 or N1 
degraders. Cells (2X105/ml) were treated with four different concentrations of degraders. L82 
(A), Karpas 299 (B) and Belli (C) cells were treated with the degrader A1, while N1 was used to 
treat IL89 (D). DMSO was used as control. After 96h and 144h of the single administration of the 
drugs, cells were harvested and lysed. Proteins were separated by electrophoresis, transferred to 
the PVDF membrane and incubated with antibodies against, total STAT3, ALK, total STAT5, and 
actin or GAPDH as a control.  
 
Next, we extended these analyses to a large set of cell lines including both ALK- 
and ALK+ ALCL, BIA-ALCL and PTCL-NOS. These included three ALCL PDTX 
models as IL2 PTCL-NOS, DN03 ALK+ ALCL and, IL142A ALK- ALCL; and on 
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TLBR1 and TLBR2, BIA-ALCLs ALK-. Cells were exposed to different 
concentrations of A1 and N1 degraders and harvested after 24h exposure.   
These data confirmed our previous findings and demonstrated a unique cell line 
sensitive to individual compounds. i.e. IL2, DNO3, and TLBR1 cells were more 
sensitive to the A1 compound, while IL142A showed more affinity for N1 (Figure 
22). Notably, TLBR1 and DN03 cells appear to be less sensitive and TLBR2 was 




Figure 22. IL2, IL142A, DNO3, and TLBR1 cells lose STAT3 when treated with the 
degraders. Cells (2X105/ml) were treated with two different concentrations of A1 and N1 
degraders. DMSO was used as control. After 24h of the single administration of the drugs, cells 
were harvested and lysed. Proteins were separated by electrophoresis, transferred to the PVDF 
membrane and incubated with antibodies against, total STAT3, ALK, total STAT5, and actin as a 
control.  
Previous data, from our group and other investigators, have shown that the loss 
of STAT3 is associated with a rapid cell cycle arrest followed by sensitive cell 
line apoptosis. To investigate possible cell cycle changes after drug exposure, 
we took advantage of a new cell cycle reporter. This vector allows the detection 
of cells in different cell cycle phases based on two fluorescent reporter probes. 
Karpas 299, Belli, and IL89 cells were first transduced with concentrated 
lentiviral preparations and followed over time. Indeed, transduced Fucci 
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lentiviral vector cells express mVenus-hGem (1/110) fused to mCherry-
hCdt1(30/120), which can distinguish three cell cycle phases as G1 by red 
fluorescence, G1/S by yellow fluorescence, and S/G2/M by green fluorescence. 
Figure 23A shows an example of the gating strategy of transduced cells before 
and after the treatment of the degraders. The double negative (untransduced, 
UT) cells were excluded from the analysis. Cells were treated with different 
concentrations of the degraders, and every 24h cells were harvested, and viable 
cells were evaluated by flow cytometry. The treatment with A1 degrader of both 
transduced Karpas 299 and Belli cells increased the fraction of cells in the G1-
arrest phase at a different time point, with a consequently decreased fraction of 





Figure 23. Karpas 299 and Belli cells 
transduced with Fucci vector are in the 
G1-arrest phase after treatment with A1 
degrader. Cells (1X106/ml) were transduced 
with the Fucci vector at the MOI of 30 (B, C) 
or the MOI of 50 (D). The 
mVenus and mCherry 
expression in transduced 
cells were measured 7 
days post-transduction by 
flow cytometry (A). Cells 
were treated with four 
different concentrations of 
A1 (B, C) or N1 (D) 
degraders. Every 24h cells 
were harvested, and 
viable cells were 
evaluated by flow 
cytometry. UT cells were 
excluded by the analysis. 
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Lastly, we tested whether we could find a synergism with a battery of 
compounds known to target selective proteins/pathways. This was achieved 
using an agnostic drug screening assay, testing the A1 and N1 degraders in 
combination with a library of 40 different drugs. We selected the L82 cell line, 
which is sensitive to the activity of both degraders. Cells were first stained with 
Cell Trace Violet dye, then seeded into 96-well plates and charged with each 
drug from the library, with or without A1 or N1. DMSO was used as a vehicle.  
After 72h, cells were stained with PI and the number of apoptotic cells was 
evaluated by flow cytometry. As depicted in Figure 24, no significant changes 
were seen between L82 treated with the library alone or in combination with 
one of the degraders. Although these data are very preliminary, they prove that 
this platform can be used to study drug synergism using a semiautomated high 
throughput approach. We are currently performing additional tests to 
investigate new combinations, multiple  PDX lines, and different readouts. 
 
 
Figure 24. Degraders in combination with the drug library do not increase the number 
of apoptotic cells. Cells (8X104/100 µL) were stained with Cell Trace Violet dye, treated with 1 
µM of each drug form the library, in combination or not with 1 µM of A1 or N1 degrader. After 72h 

















































































































































































































































































PTCLs are rare and aggressive types of NHL, characterized by low survival, poor 
outcomes, and a high rate of relapses [99]. This clinical scenario has been 
mainly related to the limited knowledge of the driving mechanisms of these 
neoplasms.  However, new molecular and functional findings have recently 
fostered the design and implementation of innovative therapeutic protocols and 
the usage of promising targeted therapies [100]. In the last decade, it has 
become evident that a subset of hematologic malignancies displays the 
constitutive activation of STAT3, drawing attention to its role as a therapeutic 
target. Among them, lymphomas have been shown to be dependent on the 
constitution activation of STAT3 signaling, driven either via ALK chimeras or by 
the somatic activating mutation of JAK1/STAT3.  [38,80]. 
Here, we focused on two pharmacological approaches to modulate the activity 
of STAT3 aiming to test in the preclinical setting new molecules that could be 
exported into the clinics.  
Our data demonstrate that ALK + ALCL cells are selectively sensitive to JPX-
XX1. Decreased metabolic rates and impaired viability were not observed only 
in ALK + ALCL cells, but also in PTCL models, leading to activating mutation of 
JAK or STAT3. In contrast, a BIA-ALCL PDX (IL89) tumor model, also carrying 
an activating JAK mutation, was extraordinarily resistant. Data suggesting that 
a genomic footprint may not be totally predictive of the response. When we 
explored the potential toxicity of these compounds, we discovered some degree 
of toxicity in peripheral blood mononuclear cells at rest or activated at very high 
concentrations (> 2µM), suggesting that a therapeutic window could potentially 
be reached. Indeed, remarkable data were seen with two new highly selective 
STAT3 degraders These molecules were proven not only to be highly specific but 
also effective and capably to maintain low STAT3 protein levels for a long period. 
More remarkably, their efficacy was achievable at very low concentration (to 50 
nM to 1µM), and more impressive was the sustained effect of the single dose 
during the time. These findings were observed with the large majority of the 
models with one single exception, IL89, a BIA-ALCL, which was frankly 
refractory. Interestingly, we found that the therapeutic efficacy of the degraders 
was linked to selective E-ligase expressed in each cell line, suggesting that 
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individual lymphoma should be tested upfront to established which E-ligase may 
be explored and those which degrader may be used. A strategy that can be 
executed likely using a limited number of biomarkers. Collectively, the 
properties of these compounds anticipate that it may be possible to establish 
the broad therapeutic window and the possibility to reach therapeutic efficacy 
with a limited amount of drugs and low overtime exposure, a scenario that may 
be associate with mild or no toxicity. Lastly, the exquisite specificity of these 
molecules makes them ideal drugs for targeting STAT3 dependent processes. 
These unique features, however, could also represent liabilities, considering that 
some neoplasms may be addicted to both STAT3 and STAT5 and/or 
compensatory circuitry (i.e. activation of alternative STAT5 pathways) may 
occur in STAT5 addicted lymphoma after STAT3 inhibition. In this latter 
scenario, someone could anticipate that responses may be delayed/tempered, 
and a possible combination of degraders target different molecules may be 
necessary.      
Mechanistically, it is known that STAT3 regulates a plethora of molecules via 
both canonical and non-canonical pathways. However, the precise mechanisms 
which operate of each tumor are still largely unclear. Our data have confirmed 
that the loss/inhibition of STAT3 can lead first to cell cycle arrest followed over 
time by cell death. Nevertheless, the rate of apoptotic cells was relatively low 
and quite variable in different models; data in line with those generated in 
patients with myeloproliferative disorders treated with JAK inhibitors, 
suggesting that prolonged exposure may be required to reach significant results. 
Based on these findings, we have envisioned to perform an agnostic drug 
screening searching for possible combinations. We believe that this approach 
may provide new avenues to define synergist activities particularly in the setting 
of ALK- ALCL or JAK/STAT3 PTCL.  
In sum, we believe that the entry of degraders in clinical settings is offering new 
and unpredictable opportunities. Indeed, these molecules may overcome the 
most difficult task of modern pharmacology, i.e. targeting transcription factors. 
Their impressive selectively, the prolonged efficacy and the potency of these 
new compounds are astonishing features, rarely achievable using conventional 
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